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ABSTRACT 
GENETIC OVER-EXPRESSION OF CYTOKERATIN 18 IN BOVINE LUTEAL CELLS: 
EFFECTS ON INTERMEDIATE FILAMENT FORMATION AND FAS LIGAND-
INDUCED APOPTOSIS 
by 
Jennifer J. Forcina 
University of New Hampshire, December 2009 
The receptor Fas and its ligand, FasL, are implicated in apoptosis 
of luteal cells during regression of the corpus luteum (CL). In some cell 
types, cytokeratin (CK) 8/18 filaments impair FasL-induced apoptosis. 
Here, we determined if genetic over-expression of CK18 filaments in luteal 
cells similarly prevents FasL-induced apoptosis. Luteal cell cultures were 
prepared from early and late stage bovine CL (day 5 and days 16-18 post-
ovulation, respectively). The cells were transduced with media, mock 
vector containing GFP, or a CK18-containing vector, and then exposed to 
a cytokine cocktail containing FasL for 24 hours. Transduction of luteal 
cells with CK18 vector resulted in CK18 aggregates rather than filaments. 
The aggregates did not affect surface expression of Fas or progesterone 
viii 
production. Moreover, the CK18 aggregates did not prevent FasL-induced 
apoptosis. Thus, while successful in transducing primary cultures of 





Significance of Dairy Cattle Infertility 
As a nutritional guide by the USDA, the food pyramid suggests 2-3 servings 
per day of milk, yogurt, and cheese products from the dairy industry [1]. 
According to USDA research, while overall milk consumption has declined from 
1909 to 2001 (with whole milk declining but lower fat milks increasing over time), 
cheese consumption in the US has increased in the same time period [2]. 
Current farms often demand high milk production from individual cows while 
managing higher numbers of cows per farm [3]. Considering milk production is 
reliant upon reproduction, it is important to have reproductively healthy cows to 
maintain high milk production while minimizing the costs associated with 
pregnancy. While milk production per cow has increased, so has the incidence 
of reproductive challenges on the dairy farm [3, 4]. For instance, "silent" estrus, 
ovarian cysts, nutritional deficiencies, and environmental factors [5] are all factors 
contributing to infertility in cows, which has resulted in reproductive failure as a 
major reason for culling dairy cows, [4, 6]. 
In order to resolve these reproductive issues, it is important to understand 
the biological reasons behind them. Reproductive failure can be a consequence 
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of problems occurring at the organ, tissue, or cellular levels. Therefore, a solid 
understanding of how these defects in biological function develop within the 
animal will help provide insight about their treatment. 
Estrous Cycle: Dairy Cow 
Improvement of fertility in the dairy cow hinges on a thorough understanding 
of the reproductive cycle in both normal and abnormal states. The estrous cycle 
in mammals consists of the cyclic reproductive state that dominates the life of the 
female. The estrous cycle typically involves the recruitment of follicles containing 
eggs, or oocytes, the development of these follicles, and the selection of at least 
one follicle to ovulate, releasing its oocyte [7], and subsequently forming the 
corpus luteum [5]. The corpus lutuem is the structure that hormonally maintains 
pregnancy following conception [5]. The estrous cycle of a cow typically is 20-21 
days, with ovulation often occurring within 24-30 hours after the onset of estrus 
[5, 8, 9]. Recruitment of follicles in cows occurs in waves, with typically 2-3 
waves of follicular recruitment during a given cycle [7]. Slight increases in 
plasma concentration of follicle stimulating hormone (FSH), which released from 
the pituitary gland, results in the selection of a cohort of follicles to begin to 
mature beyond the primordial follicle stage, with one follicle eventually exhibiting 
dominance [7] (Fig. 1). The remaining follicles undergo atresia, or programmed 
follicular death, prior to ovulation, but many follicles become atretic without ever 
being recruited to a follicular wave [7]. However, the one follicle selected to 
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ovulate is also the structure that eventually results in the formation of the corpus 
luteum[5, 8, 10]. 
Figure 1. Representative diagram of a typical estrous cycle of a cow, including 



























Ovulation, or the release of the oocyte from the dominant follicle, is a 
hormonally controlled event within the ovary. As the dominant follicle matures, 
the amount of estradiol it produces increases [7, 8, 11]. A peak in estradiol 
secretion by the preovulatory follicle induces a surge in luteinizing hormone (LH) 
that triggers ovulation [5, 7, 8, 11]. The surge in estradiol is also responsible for 
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the cow exhibiting signs of estrus, or sexual receptivity [7, 8]. After the oocyte is 
released, the follicle collapses and its remnants reorganize into the corpus 
luteum[10](Fig. 1). 
The corpus luteum (CL) is the regulatory endocrine structure that 
forms on the ovary after ovulation. The CL consists of several cell types, 
including steroid producing (steroidogenic) luteal cells, endothelial cells, 
fibroblasts, and macrophages [10, 12-15]. In all mammals, the CL is required to 
maintain pregnancy if conception occurs, but its requirement during gestation 
varies in length among species. For example, progesterone produced by the CL 
is required for approximately the first 45 days of gestation in sheep, and the first 
200 days in cows [12]. In some animals, particularly the pig, goat, rabbit and 
mouse, the CL is the main source of progesterone throughout gestation, but in 
others, such as the sheep, horse, and human, the placenta eventually serves as 
the main source of progesterone [11]. The steroid hormone progesterone is the 
major secretory product of the CL. It is the hormone that maintains pregnancy by 
reducing ovarian follicular activity and by preparing a suitable uterine 
environment and suppressing the maternal immune response [11]. However, if 
pregnancy does not occur, the CL undergoes spontaneous regression to initiate 
the next estrous cycle. 
Corpus Luteum 
The weight, volume [16], blood flow [5, 10, 12] cellular composition [13, 14], 
and functional products [16] of the CL vary throughout its life span. The lifespan 
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of the CL is typically divided into three stages: developing, functioning, and 
regressing. Additionally, the CL can be referred to as early (day 5 post-
ovulation), mid (day 10-12 post-ovulation), and late (days 16-18 post-ovulation) 
stage. In general, the weight and volume of the CL increase during the 
developing stage, are maintained throughout the functional stage, and then 
decrease as the CL regresses [5, 16] (Fig. 1). In studies describing the cellular 
composition of the CL, several investigators determined non-steroidogenic cells 
are present in higher quantities overall than steroidogenic cells [13, 14]. The 
steroidogenic cells of the CL consist of two different cell types, typically referred 
to as small and large steroidogenic cells [10, 11, 13, 14]. These small and large 
steroidogenic cells are presumably derived primarily from the thecal and 
granulosal cells of the ovulated follicle [11, 17]. 
The steroidogenic luteal cells are the sources of progesterone secretion 
within the CL [10-12], with the large cells providing more than 80% of the 
progesterone secreted by the bovine CL at mid-cycle [10]. Conversely, the 
small cells produce less basal amounts of progesterone but are the cells that are 
responsive to luteinizing hormone (LH) and consequently, increase their 
progesterone production [10-12]. There are two types of hormones that 
principally influence progesterone production by the CL: luteotropic and luteolytic 
hormones. Luteotropic hormones encourage CL growth and progesterone 
production, with LH generally recognized as the primary luteotropin in domestic 
mammals [5, 10-12, 15]. In contrast, luteolytic hormones provoke the demise of 
the CL, with prostaglandin F-2a (PGF2a) serving as the primary luteolytic 
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hormone in most non-primate species [5, 10-12, 15, 18, 19]. Regression of the 
CL is also referred to as luteolysis and involves decreased function and 
deteriorating structure of the tissue [10-12, 19]. When the CL regresses, whether 
by natural or induced methods, progesterone production decreases [10-12, 16, 
20]. The structure of the CL undergoes a process of involution [11] which 
involves the loss of cells composing the CL, in part due to apoptosis [10-12]. 
Also active in the destruction of the CL are immune cells, particularly 
macrophages, which are involved in the phagocytosis of apoptotic cells [11, 12], 
suggesting a role for the immune system in structural regression. In support of 
this concept, Korzekwa and colleagues [21] used an in vitro co-culture model to 
demonstrate that a complete decline in CL function does not occur solely in 
response to PGF2a but rather requires additional components resulting from the 
different cell types within the CL, such as endothelial cells and immune cells [21]. 
Immune System and the Corpus Luteum 
The study of the CL has been traditionally focused within endocrinology. 
Hormones not only regulate the CL but are also produced by it. However, in 
recent years the relationship between the immune system and the CL, especially 
during luteolysis, has generated a lot of interest. Very rarely do critical 
physiological events occur without some level of involvement of the immune 
system. However, the extent to which the immune system influences 
reproduction, and specifically luteolysis, is still uncertain. 
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Several immune cells have been discovered in the ovary, including 
macrophages, neutrophils, lymphocytes, eosinophils, and mast cells [22, 23]. 
Each of these cell types has different roles in immune function by virtue of the 
different products they secrete. For example, macrophages invade follicles 
undergoing atresia in both the rat [22, 24], human [22, 24], and cow [25]. A 
familiar role of macrophages is phagocytosis of cellular debris [26]. Therefore, it 
is plausible that macrophages enter atretic follicules to prevent an inflammatory 
response within the ovary. In addition, a potential role for macrophages during 
ovulation in mice [22], humans [27], sheep [28], rats [29], and pigs [30, 31], is to 
inhibit an inflammatory response post-ovulation. Neutrophils also exist in the 
ovary in high numbers at the time of ovulation in humans [27], rats [29], sheep 
[28], and rabbits [32], where their contents aid in the breakdown of the follicle 
wall and the release of the egg [31]. Therefore, immune cells are actively 
involved in many processes within the ovary. 
A considerable amount of evidence supports the contribution of immune 
cells to the function of the CL. Immune cells are found in the CL of many 
species, including pigs, cows, rabbits, rats, and humans [22, 23, 27, 29-31, 33-
46]. Macrophages and lymphocytes reside in the CL throughout its lifespan; 
however, their numbers vary among stages of the estrous cycle and between 
species [22, 30, 45]. Many studies report an increase in specific immune cells at 
the time of luteolysis, particularly macrophages [12, 22, 23, 30, 31, 36, 37, 39, 
41-43, 45, 47]. Macrophages appear to have several roles in luteal regression, 
including phagocytosis of dying luteal cells [11, 12, 31], production of cytokines, 
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particularly tumor necrosis factor-a [31], stimulation of PGF2a within the CL [12], 
and inhibition of luteal steroid production via cytokines [12, 22, 48]. 
While the increase in macrophages in luteal tissue often coincides with 
luteal regression, the role of T-lymphocytes in the CL is less clearly understood. 
T-lymphocytes serve to destroy target cells, initiate further immune response, 
and secrete cytokines, including interferon-y [26, 31]. Some studies indicate T-
lymphocytes increase as the CL ages [34, 35, 45], while others report 
consistently low numbers throughout the lifespan of the CL [27, 31, 33, 36, 39]. 
This discrepancy could be due to an inconsistency among the studies in terms of 
identifying and enumerating the subsets of T-lymphocytes. For instance, Penny 
et al. [34] reported three subsets of T-lymphocytes present in the CL throughout 
the cycle, but only two subsets increased in the regressing CL. Inconsistencies 
may also be attributable to differences among species. Numbers of T-
lymphocytes are reported to increase during regression in the cow [34, 35, 45], 
whereas T-lymphocyte numbers remain low during the late luteal phase of 
rabbits, rats [31, 33, 39], and humans [27]. 
Neutrophils are considered first responders to infections, and their roles 
include secretion of several chemokines and cytokines to attract other immune 
cells to their location [26]. Neutrophils exist in the CL of different species, but 
their distribution varies among species [27, 31, 33, 49]. Higher numbers of 
neutrophils occur in the early stages of the human and rat CL, remaining 
relatively constant as the CL ages in humans [27] while decreasing in the rat [31, 
33]. In contrast, neutrophils occur in relatively low numbers in the early porcine 
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CL [31]. Intriguingly, neutrophils are the immune cells that infiltrate the CL in 
high numbers coinciding with its demise in the golden hamster [49]. In most 
species, the quantity of neutrophils may not be as important to the regression of 
the CL as it is to the recruitment of other immune cells that contribute to its 
demise. 
MHC Molecules 
As indicated previously, T-lymphocytes populate the CL throughout the 
luteal phase. In order for T-lymphocytes to become activated and exert their 
actions, they require presentation of antigen by major histocompatibility complex 
(MHC) molecules [50]. MHC molecules exist as class I and class II molecules 
and elicit different responses in different subsets of T-lymphocytes [50]. In 
general, all cells within the body that have a nucleus express MHC class I 
molecules [50]. Therefore, it is not surprising that luteal cells express MHC class 
I molecules. However, there is conflicting information about the presence of 
MHC class I molecules on luteal cells across the lifespan of the CL. In the 
bovine CL, expression of MHC class I molecules remains relatively constant 
throughout the luteal phase [43, 51]. In contrast, MHC class I expression in the 
human increases in old or regressing CL of the previous menstrual cycle [35]. 
Unlike MHC class I expression, MHC class II molecules are often found 
only on professional antigen-presenting cells [50, 52]. MHC class II molecules 
are expressed on luteal cells in rats, cows, and humans [19, 30, 33-35, 42, 43, 
51, 53-55]. Within the bovine CL, MHC class II expression increases as the CL 
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regresses [19, 34, 51]. Both Benyo et al. [51] and Penny et al. [34] observed an 
increase in MHC class li molecules in late stage CL. Additionally, Benyo and 
colleagues [51] indicate more luteal cells express MHC class II molecules on day 
18 in non-pregnant animals than pregnant animals. In human CL, the number of 
cells expressing MHC class II molecules increases with age of the CL [35, 55]. 
However, in one study the increase occurred during the peak of the secretory 
phase [55], while another study observed the initial increase later in the cycle 
[35]. The challenges of human studies in this area include relatively low sample 
numbers due to availability of tissue and inconsistency in the terminology use to 
stage the CL. One role proposed for MHC class II molecules on luteal cells is to 
increase T-lymphocyte proliferation, during the regression of the CL [56]. 
However, lymphocyte numbers do not appear to increase in the regressing CL of 
all species, suggesting the expression of MHC class II molecules may have a 
less conventional role within the CL of certain species. 
CCL2 
Once immune cells migrate into the CL and become activated, they 
release a variety of molecules, such as cytokines, which elicit a variety of 
responses within other cells [50]. Immune cells within the ovary secrete several 
cytokines, including interferon-y (IFN-y) and tumor necrosis factor-a (TNFa) [12, 
42-44, 57, 58]. A sub-set of cytokines includes molecules called chemokines, 
which are low molecular weight peptides that often serve as chemoattractants to 
recruit additional immune cells to their location [59-62]. For example, chemokine 
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ligand 2 (CCL2) recruits monocytes [60-62] and T-lymphocytes [61], and is 
expressed in the CL prior to and during regression [38, 40, 41, 45, 59, 63-66]. 
Luteolytic hormones induce expression of CCL2, and its secretion is 
accompanied by the accumulation of monocytes/macrophages within the CL [38, 
40, 41, 59, 63]. Cavicchio et al. [67] demonstrated thatluteal endothelial cells are 
a source of CCL2 within the bovine CL and that CCL2 expression is increased by 
TNFa and IFNy. Oxygen-derived free radicals, Fas ligand, and metabolites of 
apoptosis may also stimulate expression of CCL2 [59]. Hence, it is conceivable 
that CCL2 enhances the recruitment of immune cells into the CL from the blood 
stream, and that these immune cells, in turn, may be a source of cytokines and 
further chemokine expression during luteolysis. 
IFNy 
T-lymphocytes and macrophages are both sources of IFNy [68], 
suggesting IFNy has a role in the CL of many species. In terms of luteolytic 
actions, IFNy impairs luteal steroidogenesis [69, 70], enhances prostaglandin 
production [71], and exerts cytotoxic effects [31, 71, 72], presumably through 
immune-mediated mechanisms. Moreover, IFNy increases the numbers of bovine 
luteal cells that express MHC class I and class II molecules [12, 30, 31, 42, 53, 
54, 73], indicating immune-mediated mechanisms regulate IFN secretion and 
actions. In women, IFNy decreases FSH-induced estradiol secretion [69], but not 
human chorionic gonadotropin (hCG)-stimulated estradiol production [70]. 
Additionally, IFNy decreases both basal and hCG-stimulated progesterone 
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production [69, 70] by luteal cells [22, 31]. In the cow, IFNy decreases luteal 
progesterone production, but also increases prostaglandin synthesis [30, 42, 53, 
71, 73]. In cultured bovine luteal cells IFNy is cytotoxic [31, 71, 72]. This 
cytotoxic effect is enhanced by other cytokines, notably TNFa [31, 42, 43, 72-74]. 
Collectively, these observations substantiate the perception that immune cells 
contribute to luteal regression through a variety of mechanisms. 
TNFa 
As indicated above, TNFa is another cytokine that influences luteal 
function and is found within the CL of rats, macaques, and cows [20, 75, 76]. 
Both endothelial cells [44] and macrophages are sources of TNFa within the CL 
[12, 22, 23, 43, 47]. TNFa messenger RNA (mRNA) is evident in the CL 
throughout its lifespan [43, 58, 75], but a noticeable increase in relative steady-
state concentrations of TNF mRNA is seen in regressing CL of some species, 
notably rats, macaques, and cows [20, 75, 76]. Thus, TNFa is present within the 
CL of several species and is most evident during luteal regression. Like many 
cytokines, the actions of TNFa are dependent upon binding to a specific receptor 
[77]. Messenger RNA for both TNF receptors, TNFR1 and TNFR2, has been 
demonstrated in the CL of cows [20], rats [76], and macaques [75]. The 
presence of both TNFa and its receptors in the CL of several species indicates a 
potential role for TNFa in the regulation of the CL. 
Physiological roles of TNFa are similar to IFNy, and the two cytokines 
often work synergistically. TNF impairs luteal steroidogenesis in cows, rabbits, 
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and pigs [69, 73, 78-80] and enhances prostaglandin synthesis in cows [73, 78]. 
Inhibition of progesterone production has been demonstrated in vitro in bovine 
[73, 78] and rabbit luteal cells [79]. However, this inhibition was not seen in vitro 
in porcine luteal cells [81], but was demonstrated using a microdialysis system in 
this species [80]. TNFa alone fails to inhibit both basal and hCG-stimulated 
progesterone production in human luteinized granulosa cells [69, 70]. However, 
TNFa inhibits IFNy-stimulated progesterone production by human luteal cells [31, 
70]. Additionally, TNFa impairs FSH-induced estradiol production by luteinized 
human granulosa cells [69]. TNFa exerts cytotoxic actions on cultured luteal 
cells, either alone [82] or synergistically with IFNy [31, 42, 43, 72-74]. 
Interestingly, in cultures of luteinized human granulosa cells, TNFa maintained 
basal levels of progesterone secretion for seven days, which would normally 
decrease over the time same period [69], suggesting a supportive role for TNFa 
in the human CL. The presence of TNF throughout the lifespan of the CL 
indicates it may have diverse roles within the tissue, potentially to enhance its 
function prior to enhancing its regression. 
TNF is a member of the TNF gene superfamily of protein ligands [83]. All 
the proteins in this family are thought to form trimeric structures, and they all 
induce clustering of their respective receptors at the cell surface [83, 84]. The 
activation of these receptors results in various responses, including some 
cytotoxic events and some proliferative events [84]. Another protein that exists in 
a trimeric form, and whose structure indicates its place in the TNF family of 
proteins, is Fas ligand (FasL) [50, 83-85]. Similar to TNF, FasL exists in both a 
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membrane-bound form, as well as a soluble form [85]. FasL is another cytokine 
of interest within the CL. 
FasL 
Several studies indicate FasL is expressed within the CL and influences 
luteal function. Roughton and colleagues [86] determined FasL mRNA and 
protein are expressed in the rat CL during both pregnancy and the post-partum 
period. Importantly, FasL mRNA expression increases prior to luteal regression 
(Days 16 to 22 of pregnancy) and later decreases during the postpartum period 
(Days 1 to 3 post-partum). Evidently, much of the FasL in the rat CL is derived 
from immune cells, particularly CD3+ T-cells [87]. Slot and colleagues [88] further 
characterized the localization of FasL within the rat ovary and CL to every stage 
of the estrous cycle, with the highest amounts of FasL observed in 1st and 2nd 
generation CL, but only faint detection in the 3rd generation and later. In addition, 
FasL is localized primarily to luteal steroidogenic cells of 1st generation CL, but 
present in patches of white blood cells in subsequent generation CL [88]. In the 
macaque, expression of FasL mRNA is highest in the mid-late and late CL 
compared to early CL, and FasL protein is present in both granulosal and thecal-
derived cells at all stages [75]. In the cow, FasL mRNA expression increases 
shortly after PGF2a injection, peaks at 12 hours after PGF2a, and remains 
elevated 64 hours later [20]. The presence of FasL in the CL of most species 
studied thus far has prompted further study of its action with regard to luteal 
regression and the apoptosis of luteal cells. 
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Apoptosis 
Apoptosis is a form of cell death, often called 'programmed cell death' 
because it is a highly orchestrated process for the selective elimination of cells 
without invoking an inflammatory response [89]. Apoptosis of cells can be 
signaled by a variety of stimuli, including both external stressors and conditions 
within the cell [89, 90]. There are several characteristics of apoptotic cells that 
distinguish them from cells dying by other means of cell death, such as necrosis. 
These characteristics include morphological and biochemical criteria, as well as 
genetic expression of certain relevant genes [89]. For instance, membrane 
blebbing, cell shrinkage, and the formation of apoptotic bodies (containing the 
contents of the cell) are all morphological characteristics of apoptotic cells [12, 
89-91]. Other markers include the condensation of chromatin within the nucleus, 
as well as the biochemical fragmentation of DNA into segments of characteristic 
size [12, 89-91]. Genetically, several genes serve as critical control mechanisms 
in determining whether or not a cell undergoes apoptosis, and examples include 
the genes for Fas, p53, and the bcl-2 family of proteins [89, 90], which consist of 
both pro- and anti-apoptotic proteins [50, 92]. In summary, apoptosis is a process 
of controlled death within target cells, indicated by certain morphological and 
biochemical criteria, as well as genetic regulation. Apoptosis of luteal cells 
occurs during regression of the CL, especially in ruminant animals [16, 46, 93, 
94], and is intimately linked to the structural demise of the tissue [11]. 
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Apoptosis and the Corpus Luteum 
In 1993, Juengel and colleagues [94] reported one of the hallmark 
characteristics of apoptosis within the bovine CL. The characteristic degradation 
of DNA into oligonucleosomes was shown for late stage bovine CL and CL 
obtained after PGF-induced luteolysis [94]. The fragmentation of DNA occurred 
only in regressing CL, in association with decreased progesterone production, 
implying that apoptosis occurs concomitantly with the functional loss of the tissue 
[94]. In the ewe, similar changes, characteristic of apoptosis, occur in the CL 
after PGF2a-induced luteolysis [93]. Specifically, DNA fragmentation occurs 12 
hours after PGF2a injection [93]. No evidence of DNA fragmentation was 
observed in CL of control ewes until day 14 post-ovulation [93]. Apoptotic cells 
have also been identified in the late phase of luteal regression within the 
pseudopregnant rat [95], as well as during luteolysis in the golden hamster [49] 
and human [46]. 
In addition to the observation of apoptosis within luteal cells of regressing 
CL, many of the genes involved in regulating apoptosis have been investigated in 
these cells within different species. Several members of the Bcl-2 family in 
particular have been identified in the bovine, human, and rat CL [88, 95-97]. The 
anti-apoptotic protein Bcl-2 decreases, while the pro-apoptotic protein Bax 
increases, as the CL regresses [88, 95-97]. Evidently, the ratio of Bcl-2 to Bax 
ultimately determines the fate of the cell [50, 98]. In both human and rat CL, the 
ratio of Bcl-2 to Bax decreases as the CL ages [95, 96], which favors apoptosis 
of luteal cells [98]. The Fas death receptor has been identified in the CL of 
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several species, including the cow [20, 72, 75, 86, 88, 95, 99], as has its ligand, 
FasL, as mentioned previously. Interestingly, in a recent study of the anti-
apoptotic roles of PGF2(1 in bovine luteal cells, PGF2a had no effect on either Bcl-
2 or Bax mRNA, or on the ratio of Bcl-2 to Bax, but decreased the induction of 
Fas mRNA expression by TNFa and IFNy [100]. Therefore, a least part of the 
apopotic role of PGF2a likely involves the Fas pathway. Interactions between Fas 
and FasL within the CL is of particular interest to many researchers because 
Fas-mediated apoptosis occurs within cells with and without the influence of 
mitochondrial activity [91, 101]. The potential exists that Fas-mediated apoptosis 
may occur first in CL regression, while involvement with the Bcl-2 family of 
proteins utilizing the mitochondria may occur subsequently, as indicated by 
research within the bovine CL [20]. Also, several adaptor proteins and regulators 
of the Fas pathway are elicited, but the complexity of this pathway is not yet 
clearly understood. 
FasL/Fas Pathway 
Apoptosis is induced by a variety factors involving signal ligands and their 
corresponding receptors. These cell surface receptors, called death receptors, 
are largely members of the TNFR superfamily, which transmit apoptotic signals 
[83, 91, 101, 102]. The members of this death receptor family share a conserved 
sequence within their cytoplasmic tails that is termed the 'death domain' that 
transduces the apoptotic signal [50, 83, 101, 103]. Examples of receptors within 
this family include TNFR1 and Fas/Apo-1/CD95 [50, 83, 91, 101]. The ligands 
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for these receptors belong to the aforementioned TNF superfamily of proteins, 
which includes TNF and FasL [50, 83]. In the case of FasL, it binds to its 
corresponding receptor, Fas, at the cell surface, which triggers receptor 
clustering and the organization of the death domains of the receptors [50, 83, 91] 
(Fig. 2). Collectively these molecules form the death-inducing signaling complex 
or DISC, which includes the adaptor protein Fas-associated death domain 
(FADD), the pro-form of caspase-8 [91, 101, 102], and the potentially inhibitory 
cellular FLICE-like inhibitory protein (c-FLIP; see Fig. 1 [91, 101, 103]). 
Chinnaiyan and colleagues [104] were among to first to identify FADD as a 
critical mediator of the FasL-Fas pathway. Residues 111-170 of FADD are 
identical to residues 233-292 of the Fas receptor [104], indicating the potential for 
interaction between the two molecules. Indeed, FADD associates with both Fas 
and an enhanced cytotoxic Fas mutant in co-precipitation experiments [104], yet 
does not associate with a functionally inactive mutant form of Fas. Thus, there is 
interaction between the death domains of FADD and Fas, as well as the 
presence of a death effector domain on FADD that results in death signaling. 
This death effector domain of FADD binds to the pro-form of caspase-8 (FLICE), 
which causes cleavage and activation of the enzyme, leading to activation of 
other downstream effector caspases [83, 101, 103]. Fas-mediated apoptosis can 
follow two possible pathways after activation of caspase-8: 1) cleavage of 
caspase-3 directly (type I activation) or 2) indirect cleavage of caspase-3 via the 
mitochondrial pathway (type II activation) [91, 101-103]. In either scenario, the 
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outcome is activation of caspase-3 and the eventual death of the cell by 
apoptosis. 
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The Fas receptor is itself a fascinating molecule, because of its complexity 
of ligand binding and transduction of extracellular signaling. In general, the Fas 
receptor is approximately 319 amino acids long, containing a cysteine-rich 
extracellular domain, and a transmembrane domain spanning 17 amino acids 
[105]. Human Fas (hFas) has a relative molecular weight of 43 kDa [105]. 
Within murine cells, Itoh and colleagues demonstrated that cells transformed with 
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hFas cDNA, and subsequently treated with an activating mouse anti-Fas 
antibody, underwent apoptosis as a means of cell death [105], suggesting 
aspects of FasL-Fas signaling are evolutionary conserved. In cattle, the Fas 
receptor consists of 306 amino acids and has a relative molecular weight of 46 
kDa [106]. Comparisons of bovine Fas to human and murine Fas, at the 
genomic level, indicate bovine Fas is 73% identical to human Fas and 65% 
identical to murine Fas [106]. However, the predicted protein sequence of bovine 
Fas is only 57% identical to human Fas and 50% identical to murine Fas [106]. 
Therefore, while homology exists among Fas receptor family members with 
blocks of significant conserved domains, the Fas protein does vary among 
species. Species differences must be considered when examining the functional 
role of Fas in cell death. 
Fas Receptor and the Corpus Luteum 
There is more extensive information available about the Fas receptor in 
terms of its presence and actions during luteal function than FasL. Fas receptor 
mRNA [72, 75, 86, 88, 95, 99] and protein [75, 88] are expressed throughout the 
luteal phase in certain species, with increased mRNA expression reported in 
bovine CL [20, 72] and increased protein expression in rat CL [86, 88] at the time 
of luteal regression. In the rat, Fas protein is localized mostly to the cytoplasm of 
luteal cells and is absent from endothelial cells of the CL [86, 91]. Evidence of its 
functional role in spontaneous regression of these CL is apparent by inhibiting 
luteal apoptosis with an anti-rat Fas monoclonal antibody [86]. Further evidence 
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of a Fas-mediated apoptotic pathway comes from the observation that the 
staining pattern of pro-caspase-3 is similar to that of Fas with faint, active 
caspase-3 staining in early generation CL, followed by extensive staining in late 
generation CL [88]. Within the macaque CL, Fas protein is localized to 
granulosa-luteal and theca-luteal cells in all stages of the CL, but is not detected 
in the stroma or endothelial cells [75]. These studies confirm the presence of Fas 
within the CL of certain species, localizing it to luteal cells, but not endothelial 
cells or other cell types. Overall, the FasL-Fas system may play a key role in 
apoptosis of steroidogenic luteal cells specifically and may also contribute to 
luteolysis within certain species. 
Studies of the mechanism(s) of action of Fas ligand on ovarian cells 
indicate other cytokines enhance FasL-induced effects. Within human 
granulosa/luteal cells, Quirk and colleagues [99] discovered that Fas antibody 
alone (acting as a Fas agonist) does not induce apoptosis, but requires pre-
treatment with IFNy to induce 30% apoptosis. Using bovine luteal cells, 
Taniguchi and colleagues [72] demonstrated that IFN enhances Fas mRNA 
expression and that TNF and IFN synergistically increase steady-state 
concentration of Fas mRNA. Interestingly, these authors observed that FasL 
alone does not induce apoptosis in mid-cycle bovine luteal cells [72]. 
Conversely, IFN alone induces apoptosis, but that effect is enhanced with the 
addition of TNF [72]. In addition, FasL induced death in cells treated with both 
IFN alone and IFN acting synergistically with TNF [72]. The potential exists that 
the stage of the CL may affect the susceptibility of the luteal cells to FasL, 
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potentially due to the availability of the receptor or perhaps other regulatory 
mechanisms within the cells. 
Additional molecules thought to influence Fas-mediated apoptosis of luteal 
cells include intracellular labile proteins, such as c-FLIP [91] and ceramide [107], 
which is released during receptor capping. Cycloheximide (CHX), a protein 
synthesis inhibitor, enhances Fas-mediated cell death [108], indicating proteins 
produced during the death-signaling cascade regulate the downstream effects of 
Fas activation. C-FLIP regulates caspases 8 and 10 and is involved in the 
formation of the DISC complex in the Fas signaling pathway [103]. The over-
expression of c-FLIP within cells can inhibit their apoptosis [103]. Fas-mediated 
signaling also involves ceramide release from the luteal cell membrane, an event 
associated with amplification of Fas signal transduction [107]. Pru and 
colleagues [107] determined soluble FasL increases ceramide in bovine luteal 
cells within 5 minutes of treatment, and this increase is maintained through 60 
minutes in culture. Using a ceramide analog, the authors also showed that 
ceramide induces cell death in bovine luteal cells, and this death is attributed to 
apoptosis [107]. In summary, Fas serves as a mediatior of apoptosis within 
luteal cells of several species; however, it does not act alone but rather exerts its 
effects through complex interactions likely involving several cytokines and 
transduction molecules. 
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Mechanisms Regulating Fas Expression and Action 
Fas receptor aggregation at the cell surface can occur without FasL-Fas 
interaction, a phenomenon previously observed with TNFR1 and TNF [109]. So 
what is it that regulates Fas receptor expression and aggregation within cells, 
especially when the timing of cell death is critical to the tissue? Feng and 
Kaplowitz [110] established that microtubules, a cytoskeletal element, increase 
Fas expression at the cell surface of hepatocytes. They experimentally disrupted 
the microtubules with colchicine, which increased Fas expression on the cell 
surface, but interestingly, decreased cell sensitivity to apoptosis induced by a 
Fas agonist [110]. Colchicine also increased Fas mRNA and protein expression 
within the cells [110], indicating that microtubules may directly or indirectly 
regulate the amount of Fas produced within a cell and may influence the amount 
of Fas presented at the cell surface. In 2001, Gilbert and co-workers [111] added 
to this body of knowledge about cytoskeletal elements by showing that 
cytokeratin (CK) intermediate filaments also regulate Fas expression at the 
surface of hepatocytes. In their experiments, Gilbert et al. [111] compared wild-
type hepatocytes with hepatocytes from knock-out mice in which cytokeratin 
intermediate filaments were absent. They showed that the loss of these 
filaments increases Fas-mediated apoptosis via the caspase-3 pathway [111]. 
The presence of the CK intermediate filaments in wild type mice impaired Fas 
translocation from the Golgi apparatus to the surface of the hepatocytes [111]. In 
contrast, Fas was present in high quantities on the cell surface in CK-knockout 
mice. In fact, both an increased number of cells expressing Fas at their cell 
23 
surface, as well as an increase in Fas density at the cell surface, are observed in 
CK-null mice compared to wild type mice [111-113]. These observations suggest 
that CK intermediate filaments regulate the localization of Fas within cells. 
Cytokeratins 
Cytokeratins are a component of the cytoskeleton, which contribute to the 
structure and integrity of cells. There are three principle types of filament 
systems that comprise the cytoskeleton: microfilaments, microtubules, and 
intermediate filaments (IF) [112-116]. Intermediate filaments are intermediate in 
size between the other two components [112-116] and, as indicated above, are 
thought to influence aspects of Fas-mediated apoptosis. Intermediate filaments 
consist of at least five different groups of proteins, including type I and type II 
proteins, which are sub-groups of cytokeratins [112, 113]. Cytokeratin (CK) 
intermediate filaments are obligate heterodimers of a single type I and type II 
cytokeratin [113, 115], meaning that intermediate filaments must consist of at 
least one type I CK paired with one type II CK. The molecular weight of 
cytokeratins ranges from ~40-68kDa [114, 115]. Type I cytokeratins (CK9-20) 
are typically small, acidic, and located on chromosome 17, except for CK18 [US-
US]. Type II cytokeratins (CK1-8) are typically large, basic, and located on 
chromosome 12 [113-115]. CK18 is located on chromosome 12, adjacent to 
CK8 [113]. CK8 and CK18 are found in similar cells and tissues within the body, 
and they are the only intermediate filaments found in hepatocytes [114]. Due to 
CK8/18 intermediate filaments being the only CK intermediate filaments in 
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hepatocytes, these cells allow for investigation into the functions of CK8/18 in 
cells. Even though the role of CK8/18 intermediate filaments may differ among 
cells, the information attained from studies in these cells may indicate the 
potential for similar functions of CK8/18 filaments in other cell types. 
Cytokeratins and the Corpus Luteum 
CK intermediate filaments have been identified within the CL of women, 
cows, and rats [117-120]. While CK18 is one of proteins contained within CK 
intermediate filament dimers of the bovine CL [117, 118], CK8 has been 
identified as its partner in human [119] and rat [120] CL. As determined by 
immunohistochemistry, the amount of cells expressing CK18-containing 
intermediate filaments decreases as the bovine CL ages. These results were 
confirmed quantitatively by flow cytometry. Specifically, the percentage of CK 
positive cells decreased from -33% of the cells in early stage to ~5% in late 
stage CL [118]. These results raise the question of whether or not CK 
intermediate filaments influence the susceptibility of luteal cells to apoptosis in 
the CL similarly to the way they influence apoptosis of hepatocytes in the liver. 
Hypotheses 
Currently, there is limited information available about the expression of 
Fas protein in luteal cells, and specifically, expression at the cell surface. 
Similarly, the mechanisms controlling apoptosis of luteal cells via Fas-FasL 
interactions are poorly understood. The current study investigated the expression 
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of Fas both in and on bovine luteal cells from early and late stage CL and 
attempted to determine if CK18 intermediate filaments play a role in regulating 
Fas expression. Specifically, this study implements genetic over-expression of 
CK18 within bovine luteal cells to assess the effect on FasL-induced apoptosis. 
The hypotheses tested were as follows: 1) Total Fas protein will increase from 
early to late stage in the bovine CL. 2) Surface expression of Fas will increase 
as the CL ages. 3) Over-expression of CK18 filaments will inhibit expression of 
Fas at the cell surface. 4) Additionally, over-expression of CK18 filaments will 
prevent FasL-induced apoptosis. 
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CHAPTER II 
GENETIC OVER-EXPRESSION OF CYTOKERATIN 18 IN 
BOVINELUTEAL CELLS: 
EFFECTS ON INTERMEDIATE FILAMENTFORMATION AND 
FAS LIGAND-INDUCED APOPTOSIS 
Introduction 
Infertility of dairy cows has become a major concern for the dairy 
industry [4, 6, 121]. Reproductive abnormalities within a herd result in 
increased costs and therefore decreased profits for dairy farmers [4]. A 
thorough understanding of the reproductive process from the molecular to 
the physiological level is needed to address these concerns. Previous 
research supports a strong presence of immune cells in the corpus 
luteum (CL) [19, 20, 22, 23, 27, 30, 31, 33-46, 49, 122]. In addition, we 
know that 'programmed cell death' or more specifically, apoptosis, 
contributes to the demise of the CL through elimination of individual luteal 
cells [11,16, 44, 46, 49, 93, 94, 122], and a role for immune cells in luteal 
regression has been implicated [12, 19, 20, 22, 31, 35, 44, 48]. However, 
there is a general lack understanding of the cellular mechanisms 
regulating immune-mediated apoptosis within the CL and how these 
mechanisms influence aspects of luteal function. 
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Several cell types comprise the tissue of the CL, including steroid-
producing (steroidogenic) luteal cells, endothelial cells, fibroblasts, 
pericytes, and immune cells [10, 12-15, 44]. Many types of immune cells, 
including macrophages, neutrophils, lymphocytes, eosinophils, and mast 
cells exist within the CL of many species, including pigs, cows, hamsters, 
rabbits, rats, and humans [22, 23, 27, 30, 31, 33-46, 49]. Many of these 
studies report an increase in specific types of immune cells at the time of 
luteolysis, particularly macrophages [12, 22, 23, 30, 31, 36, 37, 39, 41-45, 
47]. Immune cells release a variety of effector molecules, termed 
cytokines, which elicit desired responses from a variety of cell types, and 
chemokines, which recruit additional immune cells [50]. Within the ovary, 
immune cells produce such cytokines as interferon-y (IFN-y), tumor 
necrosis factor-a (TNFa) [12, 20, 42-44, 57, 58, 95, 123], and Fas ligand 
(FasL) [75, 86-88, 124, 125], and chemokines such as chemokine ligand 
2 (CCL2) [60-62]. Many cytokines and chemokines elicit responses in 
target cells via interactions with their receptors on the cell surface. For 
instance, both TNFa and FasL bind death receptors of the same protein 
family and can ultimately initiate cell death within the target cell [83, 85, 
101]. 
FasL mRNA and protein have been identified in the CL of many 
species, including the rat, macaque, and cow [20, 75, 86-88]. Within 
these species, the Fas receptor has also been identified, as well as in 
human CL [44, 72, 75, 86, 88, 91, 95, 99]. Previous studies indicate a 
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role for Fas-mediated apoptosis of luteal cells [44, 72, 86, 99] in 
regression of the CL. Both Fas mRNA in the cow [20, 72] and Fas 
protein in the rat [86, 88, 95] increase at the time of luteal regression. In 
addition, DNA fragmentation occurs during luteal regression, indicating 
apoptosis of luteal cells in both cows and sheep [16, 93, 94]. Roughton 
and colleagues [86] confirmed the role of Fas within the CL as a means 
of apoptosis by demonstrating a decrease in apoptosis of luteal cells after 
the addition of an anti-rat Fas monoclonal antibody. Other studies have 
also demonstrated a role for IFNy and TNFa in Fas-mediated apoptosis 
within the CL, either by enhancing the efficacy of Fas agonist antibody or 
by increasing Fas mRNA [44, 72, 99]. 
A relatively unexplored area of research in the ovary the 
mechanism(s) regulating Fas expression at the cell surface and the 
influence on Fas-mediated apoptosis. Several recent studies of 
hepatocytes indicate cytoskeletal elements control the trafficking of Fas 
to the cell surface [110-113]. In particular, CK8/18 intermediate filaments 
influence the density of Fas receptor on the cell surface [111]. Gilbert 
and colleagues [111] utilized knockout mice to manipulate the only 
intermediate filament pair found within hepatocytes: CK8/18 [114]. Within 
wild-type hepatocytes expressing CK8/18 filaments, Fas was localized to 
the Golgi complex, yet within CK8-null hepatocytes lacking those 
filaments, Fas migrated in abundance to the cell surface [111]. In 
addition, the hepatocytes of CK8-null mice were more susceptible to Fas-
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mediated apoptosis than wild-type mice [111]. CK intermediate filaments 
occur in the CL of women, rats, and cows [117-120]. Both CK8 and 
CK18 are evident in human [119] and rat CL [120], and CK18-containing 
filaments are present in the bovine CL [117, 118]. However, as the 
bovine CL ages, the number of cells expressing CK18-containing 
intermediate filaments decreases, coinciding with the period of luteal 
regression [118]. 
Several important events occur in the bovine CL as it regresses. 
Firstly, as the CL ages, Fas mRNA increases [72]. Secondly, the 
structural demise of the CL involves apoptosis of individual steroid-
producing luteal cells [11, 16, 44, 46, 49, 93, 94, 122]. Finally, the 
abundance of CK18-containing steroidogenic luteal cells decreases in 
relation to CL age [118]. A role for the Fas receptor within the CL has 
been linked to CL regression [44, 72, 86, 99]. Based upon research with 
hepatocytes, a potential role for CK8/18 intermediate filaments to control 
Fas receptor expression exists [111]. Could CK18-containing 
intermediate filaments within the bovine CL have a similar role in 
Influencing Fas receptor expression on luteal cells? 
The current study explored the potential for CK8/18 filament 
regulation of Fas density on the surface of bovine luteal cells, specifically 
focusing on the results of genetic over-expression of CK18. Freshly 
dissociated luteal cells from early and late stage CL were assessed for 
expression of CK18, total Fas, and surface Fas. An adenovirus vector 
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was utilized to genetically over-express CK18 within cultured luteal cells 
of early and late stage bovine CL. Effects of CK18 genetic over-
expression were assessed in regard to cell function, cellular integrity, 
expression of Fas, and responsiveness to FasL-induced apoptosis 
Materials and Methods 
Reagents 
Plastic culture vessels used were Becton-Dickinson (Franklin 
Lakes, NJ) purchased through Fisher Scientific (Pittsburg, PA). Glass 
slides, coverslips, and sodium citrate were purchased from Fisher 
Scientific. Collagenase, type I, was purchased from Worthington 
Biochemical Company (Lakewood, NJ). Bovine serum albumin (BSA) 
was purchased from MP Biomedicals Inc. (Solon, OH). Ham's F12 and 
gentamicin (Gibco) were purchased from Invitrogen (Carlsbad, CA). 
Trypsin-EDTA was purchased from MediaTech (Manassas, VA). Fetal 
bovine serum (FBS) from Gibco was a gift to the UNH cell culture class. 
Hank's Balanced Salt Solution (HBSS), trypan blue, ITS (insulin, 
transferrin, selenium; 5[ig/5fxg/5ng/ml_), bovine deoxyribonuclease 
(DNase) I, and paraformaldehyde (PFA) were purchased from Sigma-
Aldrich (St. Louis, MO). CO2 tanks were purchased from Airgas (Radnor, 
PA). Hydrochloric acid was purchased from EM Sciences (North 
Vancouver, British Columbia). Normal goat serum (NGS) was purchased 
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from Vector Laboratories (Burlingame, CA). Triton X-100 and Tris base 
were purchased from J.T. Baker Chemical Company (now Mallinckrodt 
Baker, Inc., Phillipsburg, NJ). DAPI mounting medium was purchased 
from both Invitrogen and Vector Laboratories. Bovine interferon-y (IFN), 
recombinant human Fas ligand (FasL), and murine monoclonal anti-6x 
histidine cross-linking antibody were purchased from R&D Systems 
(Minneapolis, MN). Murine tumor necrosis factor-a (TNFa) was 
purchased from US Biologicals (Swampscott, MA). 
Mixed Luteal Cell Culture 
Corpora lutea from early (day 5) and late (day 16-18) stages of the 
estrous cycle (ovulation = day 0) were obtained by transvaginal 
luteectomy and enzymatically dissociated, as described previously [126]. 
In brief, pieces of tissue were snap frozen in liquid nitrogen for RNA and 
protein analysis. The remaining tissue from the CL was sliced, cut into 
small pieces, minced, and dissociated 2-3 times using a collagenase type 
I solution (dissolved in Ham's F12 medium containing 200[xL gentamicin 
and 0.5 g BSA per 100mL) and a mechanical spinner flask for 1 hour 
incubations at 37°C with manual pipetting up and down every 10 minutes. 
After each dissociation, cells were carried through a series of rinses in 
ice-cold Ham's F12 with gentamicin and centrifuged at 4°C. After the 
cells were rinsed, they were counted using a hemocytometer and 
assessed for viability via trypan blue exclusion method. The cells were 
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seeded into T25 flasks at 1.5x106 viable cells/flask and into 12-well plates 
containing acid-washed coverslips at 300,000 viable cells per well and 
were cultured in Ham's F12 with 10% FBS and gentamicin overnight at 
37°C, 5% C02 in air with 95% humidity. After the dissociation and cell 
seeding, the remaining freshly isolated cells were filtered through screen-
cap tubes at 1.5x106 viable cells per tube and fixed in 1% PFA for 2 hours 
on ice. 
Analysis of Freshly Dissociated Cells for CK18 and Fas 
Freshly dissociated luteal cells from early (day 5) and late (day 16-
18) stage bovine CL were diluted to 1.5x106 cells per 300[o,L of Ham's 
F12, and 300[j,L was added to the top of the screen cap of each tube. 
The cells were centrifuged at 514xg, 4°C for 10 minutes. Within each 
tube, 100[AL of Ham's F12 was added, followed by 400^1. of 2% PFA in 
PBS, to essentially fix the cells with a 1% paraformaldehyde solution. 
The cells were re-suspended in the tubes, and the tubes were wrapped in 
parafilm and incubated on ice for two hours, with occasional flicking. 
After the two hours, the cells were either held in the fixative at 4°C until 
staining or were centrifuged at 276xg, 4°C for 5 minutes. The 
supernatant was poured off, and cells were then rinsed with 4mL PBS. 
Subsequently, the cells were centrifuged for 5 minutes at 276xg, 4°C. 
This step was repeated, and then cells received 1ml_ of ice-cold 70% 
ethanol for permeabilization. These tubes were wrapped in parafilm as 
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well and stored at -20°C until staining. Permeabilized cells were used for 
total staining of CK18 and Fas, whereas cells remaining in the initial 
fixative were used for staining of Fas expression on the cell surface. 
For CK18 staining, cells were centrifuged at 276xg, 4°C for 5 
minutes, and the supernatant was poured off. The cells were rinsed with 
1ml_ PBS containing 0.1% BSA, and centrifuged as described above. 
This step was repeated, and then the cells were exposed to either IOOJAL 
of PBS containing 1% BSA (negative control), mouse lgG1-FITC at 1:100 
in PBS containing 1% BSA (isotype control), or mouse anti-human CK18-
FITC at 1:100 in PBS containing 1% BSA. The tubes containing the cells 
were wrapped in parafilm and incubated for 1 hour at 37°C. Afterward, 
the cells were rinsed twice in PBS as described prior to staining. The 
cells were then held in 0.5ml_ PBS/tube until analyzed on the flow 
cytometer. 
For Fas staining (both total and surface), the rinses and centrifuge 
details were identical to the CK18 staining. For incubation with primary 
antibody, however, the cells were exposed to either 100^L PBS 
containing 1% BSA, 10% NGS (negative control) or mouse anti-human 
Fas antibody (clone CH-11, Millipore) at a 1:25 dilution in PBS containing 
1% BSA, 10% NGS. The tubes were subsequently wrapped in parafilm 
and incubated overnight at 4°C. These cells were then rinsed twice and 
incubated for 1 hour with goat anti-mouse Alexa 488 at 1:100 in PBS 
containing 1% BSA and 10% NGS (secondary antibody, Invitrogen) at 
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37°C, with the tubes wrapped in parafilm. After the secondary antibody 
incubation, the cells were rinsed twice and re-suspended in 0.5ml_ PBS 
for flow cytometric analysis. The negative controls, either lgG1-FITC for 
CK18 or Alexa-488 secondary antibody only for Fas, were used to set the 
fluorescence gating to 1% positive controls prior to analysis. The cells 
were recorded on the FL-1 filter at no more than 800 events/second with 
a total of 10,000 recorded events. When possible, duplicate tubes per 
cow were run for each marker. Graphs were composed using Win-MDI 
v.2.9 free software. 
Immunoprecipitation and Western Blot Detection of CK8/18 
Filaments 
To verify that cytokeratin intermediate filaments in the bovine 
corpus luteum consist of heterodimers of CK8 and CK18, a small portion 
of snap-frozen CL tissue was subsequently prepared for 
immunoprecipitation and western blot analysis. Briefly, the snap-frozen 
tissue was homogenized in 1.5 ml immunoprecipitation lysis buffer (50 
mM Tris-HCI, pH 8.0, 137 mM NaCI, 2 mM EDTA, 10% glycerol, and 1% 
triton X-100; with 10 uL protease inhibitor, 10 uL 0.1 M DTT, and 10 uL 
PMSF per ml of buffer just before use) using a mortar and pestle. The 
lysate was transferred to a microcentrifuge tube, vortexed briefly, and 
then incubated on a rotary shaker for 30 min at 4°C. Subsequently the 
lysate was centrifuged and the supernatant, containing the sample, 
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transferred to a new microcentrifuge tube. The supernatant was then 
pre-cleared by mixing 2 mg of sample in 1 ml volume with 10 uL normal 
rabbit serum and 50 ul protein-G Agarose beads (beads were washed 
with lysis buffer 5 times prior to use) with gentle shaking at 4°C for 1 hr. 
This step was followed by centrifugation at 12,000xg for 30 seconds and 
transfer of the supernatant to a new microcentrifuge tube. Ten microliters 
(10 uL) of the mouse monoclonal anti-human cytokeratin-18 antibody 
(clone CY-90, Sigma) was added to the sample followed by incubation 
overnight at 4°C with shaking. Then, 50 uL of pre-washed homogenous 
Protein G was added to the sample followed by incubation at 4°C for an 
additional hour. The sample was centrifuged at 12,000xg for 30 
seconds, the supernatant was carefully removed, and the remaining 
pellet, containing the precipitated agarose-antibody-antigen complexes, 
was re-suspended and washed with 0.5 ml_ lysis buffer for 5 min at 4°C, 
with shaking. This wash procedure was repeated two additional times. 
Following the last wash, the agarose pellet was re-suspended in 30 uL of 
4X non-reducing sample buffer, 12 uL of reducing buffer, and 18 uL of 
ddH20. The proteins were eluted from the beads by heating the 
suspension to 95°C for 10 min. For a negative control, 2 uL (2 ug) of non-
specific mouse IgG was used in place of the monoclonal anti-CK18 
antibody. The eluted proteins were resolved by SDS-PAGE and then 
probed by western blot analysis using a mouse anti-human CK8 antibody 
(clone C51, Santa Cruz Biotechnology, Inc., Santa Cruz, CA). 
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Adenovirus Transduction and Cytokine Treatment 
An adenovirus serotype 5 vector was used for the transduction 
experiments. Vectors were obtained from Dana Farber/Harvard Cancer 
Center Vector Core Facility (Boston, MA) and contained a bidirectional 
cytomegalovirus promoter (CMV; Fig. 3). The early 1 (E1) and early 3 
(E3) genes were deleted from the viral vector to incorporate our gene of 
interest and to render the virus 'replication-deficient' [127]. The E1 gene 
codes for proteins necessary for viral transformation [128]. The E1A 
gene is required for activation of all other early genes [127, 128], while 
the E1A and E1B genes work together to mediate cellular transformation 
by adenovirus [128]. The E3 gene is linked mostly to modulating the host 
immune response to adenovirus infection, potentially through binding 
MHC peptides [127, 128]. Adenovirus serotype 5 has a 36kb DNA 
genome, which allows up to 2kb of foreign DNA to be inserted into it. 
However, by deleting the E1 and E3 genes, an insert up to 7kb can be 
introduced into the viral genome [127, 128]. These viral vectors can be 
generated as high titer stocks and they will infect a broad range of host 
mammalian cells, including both dividing and non-dividing cells [127, 
128]. In the current study, it is important for the vector to transduce 
primary cultures of non-dividing luteal cells. 
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Figure 3. General structure of the replication-deficient adenovirus vector 
used for the transduction experiments. Adapted from 
http://hqti.med.harvard.edu/pp/Ad-BGFP-Cla.Dna [129]. 
Structure of Ad-BGFP-Cla 
32,698 bp 
Capacity -3,250 bp 
ITR Adenovirus serotype 5 ITR 
Transduction treatments consisted of no virus (CTL), mock 
adenovirus containing the gene coding for green fluorescent protein 
(Ad.GFP), and adenovirus containing the gene for GFP, as well as the 
target gene coding for the gene for CK18 (Ad.CK18). Adenovirus stocks 
of Ad.GFP and Ad.CK18 were diluted appropriately to obtain a multiplicity 
of infection (MOI) of 40 for each culture vessel, thereby introducing 40 
viral particules/cell into the cultures. Adenovirus vectors were added to 
the cultures in minimal fresh media and incubated for 1-1.5 hours at 37°C 
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in a humidified atmosphere. After the incubation, new Ham's F12 
containing ITS and gentamicin was added to each well (1mL) and flask 
(5mL). Cells were incubated for 16-24 hours at 37°C in a humidified 
atmosphere (protocol adapted from that provided by Dr. John Davis, 
UNMC, Omaha, NE; see appendix). 
Following initial culture and transduction, the cells were then either 
fixed with 4% PFA or treated with a cytokine cocktail for 24 hours. The 
cytokine cocktail consisted of IFN (200 U/mL), TNFa (10ng/mL) [74], 
FasL (50ng/mL), and cross-linking antibody (1mg/ml_) [118]. After 
administrating the cytokine cocktail, plated cells were counted in 3 fields 
of view (FOV) per well to determine viable cells at the initiation of 
treatment. After 24 hours of culture, the number of plated cells was 
counted again to determine cell viability (3 FOV/well). Subsequently, the 
cells were then fixed in 4% PFA for additional cell viability analysis. 
Conditioned media was collected for analysis of progesterone production. 
Immunostaining of CK18 and Microtubules in Transduced Luteal 
Cells 
After fixation, the cultures of luteal cells were rinsed with PBS and 
subsequently held in PBS at 4°C until staining. The culture vessels were 
wrapped with parafilm to prevent dessication. For staining, the cells were 
rinsed 3x for 5 minutes each in PBS containing 0.1% BSA and then 
treated with PBS containing 3% BSA, 10% NGS, 0.3% Triton X-100 
39 
(blocking/permeabilizing solution) for 1 hour at RT. Immediately 
afterward, this solution was replaced with 300jxL primary mouse anti-
human CK18 anitbody (clone CY-90, Sigma) at 1:800 dilution or primary 
mouse anti-bovine a-tubulin antibody (clone 236-10501 Invitrogen) at 
1:200 in PBS containing 1% BSA, 10% NGS, 0.3% Triton X-100. The 
cells were incubated with primary antibody overnight at 4°C and placed 
on a gently rocking platform. After the primary antibody incubation, the 
cells were rinsed 3x for 5 minutes each in PBS containing 0.1% BSA. 
For secondary antibody, 300[iL of goat anti-mouse IgG conjugated with 
Texas Red (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) at 1:100 
dilution in PBS containing 1% BSA, 10% NGS, 0.3% Triton X-100 was 
incubated with the cells for 1 hour at 37°C. After incubation with the 
secondary antibody, the cells were rinsed 3x for 5 minutes each in PBS 
containing 0.1% BSA and mounted onto glass slides using DAPI 
mounting medium as a nuclei counter-stain. Cells were imaged using an 
Olympus BX51 microscope, Q-imaging camera, and Q-capture v2.8.1 
software. Negative controls consisted of cells receiving no primary 
antibody followed by secondary antibody dilution. 
Immunostaining of Fas Surface Expression on Transduced Luteal 
Cells transduced in flasks were rinsed with 5ml_ HBSS modified 
without calcium and magnesium ions, followed by 0.5mL trypsin-EDTA 
solution added to each flask to release the cells. With the trypsin solution 
40 
still in the flask, 4mL of 4% PFA was added. The cells were fixed for 30 
minutes at RT and then poured into new 5mL centrifuge tubes, where 
they were fixed on ice for an additional 90 minutes. After fixation, the 
tubes of cells were wrapped with parafilm and held in the fixative at 4°C 
until the day before staining. The day before staining, the cells were 
centrifuged at 146xg for 10 minutes at 4°C, and then re-suspended in 
fresh 2-4% PFA. Once re-suspended, the cells were added to screen-
cap tubes and spun at 276xg for 10 minutes at 4°C. Cell pellets re-
suspended in fresh 2-4% PFA were held on ice for 2 hours prior to 
refrigeration (4°C) overnight. The next day, the cells were washed by 
centrifuging at 276xg for 5 minutes at 4°C, rinsing with 1ml_/tube PBS 
containing 0.1% BSA, and then centrifuging again. The wash steps were 
repeated, and the cells were then incubated with 100[xL of primary mouse 
anti-human Fas antibody (clone CH-11 antibody, Millipore, Billerica, MA) 
at 20mg/ml_ (1:25) in PBS containing 1% BSA, 10% NGS at 4°C 
overnight. After the overnight incubation, cells were rinsed twice in 
1ml_/tube PBS containing 0.1% BSA and then incubated with secondary 
goat anti-mouse APC-conjugated antibody (Santa Cruz Biotechnology, 
Inc.) at 1:200 dilution in PBS containing 1%BSA, 10%NGS for 1 hour at 
37°C. After incubation with the secondary antibody, the cells were 
washed twice with 1ml_/tube PBS containing 0.1% BSA and finally re-
suspended in 0.5mL/tube PBS prior to flow cytometric analysis using a 
Becton-Dickinson FACSCalibur Flow Cytometer (UNH Instrumentation 
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Center). Cells exposed to secondary antibody only were used as the 
negative control with gating set at 1% of the cell population. Cells 
transduced with Ad.GFP were used to set the 1% GFP positive cells for 
GFP analysis. For flow cytometry, 10,000 cells (events) were recorded 
for the data set, at a rate of less than 800 events/second using the FL-1 
filter for GFP detection and the FL-4 filter for APC detection. Results 
were analyzed using Win-MDI v.2.9 free software. 
TUNEL Staining of Transduced Luteal Cells Exposed to Cytokine 
Cocktail 
Luteal cells were stained for apoptosis using the In Situ Cell Death 
Kit, TMR red from Roche Applied Science (Indianapolis, IN). Prior to 
staining, the cells were rinsed twice with PBS and then fixed for 30 
minutes at RT in 4% PFA in PBS. Subsequently, the cells were stained 
following the manufacturer's instructions. In brief, the cells were rinsed 
twice with PBS, permeabilized for 2 minutes on ice using 1ml_/coverslip 
of 0.1% sodium citrate containing 0.1% Triton X-100 (permeabilizing 
solution, made fresh), and rinsed twice with PBS. Positive control cells 
were then exposed to 0.1mg/mL bovine DNase in 50mM Tris-HCL, pH 
7.5, 1mg/mL BSA for 10 minutes at RT. Remaining cells were exposed 
to 50mM Tris-HCI, (pH 7.5) simultaneously. The cells were then rinsed 
twice with PBS prior to addition of the TUNEL Reaction Mixture. 
Following the kit protocol, enzyme solution was diluted 1:10 in the label 
42 
solution and used at 50>L per sample. Negative control cells were 
exposed to 50>L of the label solution only. Parafilm was placed on each 
sample, and the samples were incubated with the TUNEL Reaction 
Mixture for 1 hour at 37°C in a humidified chamber. The cells were then 
rinsed 3x with PBS and mounted onto glass slides using DAPI mounting 
medium as a nuclei counter-stain. The cells were imaged using Q-
Capture with 3 fields of view per coverslip, with two images from each 
side of the well and one image from the center. Overall, there were 3 
images/sample, with 2 samples/treatment group, and images were 
captured using the 10x objective. The number of TUNEL-positive cells in 
each image was quantified by two independent observers who were blind 
to the various treatment groups. In addition, the total number of DAPI-
stained nuclei per image was used to express the results as a percentage 
of TUNEL-positive cells relative to the total number of cells. There was 
99% agreement in percent of TUNEL-positive cells between the two 
observers. 
Progesterone Analysis of Conditioned Media 
Progesterone in the conditioned culture medium was analyzed 
using a Radioimmunoassay (RIA) Progesterone Kit (catalogue #DSL-
3400) from Beckton Coulter, Inc. (Fullerton, CA). The assay was 
performed according to kit protocol, and the coefficent of variation for this 
assay was 8.99% with a standard deviation of 3.5 
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Analysis of Serum Progesterone 
Blood was also removed from the cow prior to luteectomy for 
analysis of serum progesterone. Blood was centrifuged at 914xg, 4°C, 
for 15 minutes. The supernatant (serum) was removed and stored at -
20°C until day of extraction. Serum progesterone was analyzed via RIA 
as described previously [130]. 
Statistical Analysis 
For flow cytometric analyses of freshly isolated luteal cells, 
experiments included 4-9 different CL replicates/stage. For 
immunohistochemical staining, experiments were replicated with 3-4 
CL/stage. Apoptosis and cell death data were acquired from a minimum 
of 2-3 CL/stage. Flow cytometric analysis of Fas surface staining of 
transduced cells was performed on cells from 3 late-stage CL. Analysis 
was performed on the means using a one-way analysis of variance 
(ANOVA) in the general linear model of Systat 10 (Chicago, IL) with 
stage, treatments, and interactions between treatments and stage. When 
appropriate, Tukey's multiple comparison test was used to distinguish 
between treatment means. If treatments were performed in replicates on 
a single CL, the mean of the results was used in the statistical analysis. 
Significance is set at P<0.05. 
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RESULTS 
Cytokeratin-18 Expression in Bovine Luteal Tissue 
A previous study initially demonstrated that the number of cells 
expressing CK18 decreases as the CL ages [118]. The present study 
confirmed these findings with extensive flow cytometric analysis. The 
percentage of cells expressing CK18 in sample preparations from early 
stage CL was greater than those from late stage CL (Fig. 4a, P<0.05), 
averaging 46% ± 3% for early CL and 26% ± 3% for late CL. Early stage 
CL were also used to determine whether the CK-containing intermediate 
filaments in these cells consisted of heterodimers of CK8 protein 
associated with CK18. Western blot analysis with anti-CK8 antibody, 
following immunoprecipitation of luteal lysates utilizing anti-CK18 
antibody (Fig. 4b), revealed dimerization of CK8 with CK18. In total luteal 
lysates, CK8 was readily detectable at the relative molecular weight of 52 
kDa (Fig. 4b, lane 1). Immunoprecipitation with a non-specific, 
monoclonal IgG resulted in no detection of CK8 (Fig. 4b, lane 2). In 
contrast, immunoprecipitation with the monoclonal, anti-CK18 antibody 
revealed a relative enhancement of CK8 protein (Fig 4b, lane 3). The 
anti-CK18 antibody used here was also utilized for flow cytometric and 
immunofluorescent analysis throughout this study. 
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Expression of Fas on Bovine Luteal Cells 
Freshly dissociated luteal cells from early and late stage CL were 
characterized for total Fas expression and Fas expression on the cell 
surface (Fig. 5). A higher percentage of luteal cells expressed Fas in 
early stage CL compared to late stage CL (Fig. 5a, P<0.05). Moreover, 
more cells from early stage CL expressed Fas on the cell surface than 
cells of late stage CL (Fig. 5b, P<0.05). A comparison of the percentage 
of cells expressing Fas on the cell surface relative to total Fas expression 
revealed that cells from early stage CL express the majority of Fas (76%) 
on the cell surface (Fig. 5c). A confocal image of a luteal cell revealed 
foci of Fas staining (green) largely at the cell surface (Fig. 5d). 
Transduction of Cultured Bovine Luteal Cells With CK18-Containing 
Adenovirus 
The effect of CK18 adenovirus transduction on cultured bovine luteal 
cells from early and late stage CL was assessed by fluorescence 
microscopy. In early stage CL, GFP was undetectable in vehicle-treated 
wells (Fig. 6b), as expected, but clearly evident in cultures exposed to the 
mock vector (Ad.GFP) and the CK18-containing vector (Ad.CK18; Figs. 
6f and 6j, respectively). Uptake efficiency was assessed by visual 
estimation of GFP-positive cells, which was 53.6% and 67.3% for 
Ad.GFP and Ad.CK18, respectively. In cultures exposed to Ad.CK18, 
transduction resulted in aggregation of CK18 protein rather than over-
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expression of CK18-containing intermediate filaments (Fig. 6k). In 
contrast, no aggregation was observed in vehicle and Ad.GFP-treated 
cultures (Figs. 6c & 6g, respectively). Rather, CK18 protein was detected 
within filamentous structures, as expected. CK18 aggregates were 
morphologically distinct from filamentous structures within the luteal cells 
and appeared as foci of intense, punctate staining (Fig. 7). 
Similar results were observed in cultures using cells of late stage 
CL (Fig. 8). That is, GFP was undetectable in control cultures (Fig. 8b), 
but was observed in Ad.GFP and Ad.CK18 cultures (Figs. 8f & 8j, 
respectively). Adenovirus uptake efficiency was estimated at 44.6% and 
51.5% for Ad.GFP and Ad.CK18 cultures, respectively. As before, 
aggregates of CK18 protein, rather than over-expression of filaments, 
was seen in all Ad.CK18-transduced cultures (Fig. 8k). No CK18-
containing aggregates were seen in vehicle or Ad.GFP-transduced 
cultures (Figs. 8c & 8g, respectively). 
Adenovirus Transduction Does Not Affect Microtubule Formation 
There was no effect of adenovirus transduction on microtubules in 
cultured bovine luteal cells from early (Fig. 9) and late stage CL (Fig. 10). 
In all instances, microtubules remained intact and filamentous in control 
(Fig. 9c), Ad.GFP- (Fig. 9g), and Ad.CK18-transduced cultures (Fig. 9k) 
from early stage CL. Similarly, in cultures from late stage CL, 
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microtubules remained intact in control cells (Fig. 10c) and cells 
transduced with either Ad.GFP (Fig. 10g) or Ad.CK18 (Fig. 10k). 
Effects of Transduction on Fas Surface Expression on Bovine Luteal 
Cells 
In cultures of bovine luteal cells from late stage CL, transduction with 
Ad.GFP and Ad.CK18 impaired Fas surface expression by 18% and 
41%, respectively, in a single experiment (Fig. 11a). In subsequent 
experiments, however, these trends diminished such that, overall, no 
detectable difference in Fas surface expression was observed among the 
treatment groups (Fig. 11b, P>0.05). Moreover, there was no effect of 
treatment on relative mean fluorescence intensity of Fas expression (i.e. 
relative receptor density) in the experiments (Fig. 11c, P>0.05). 
Effects of Transduction and Cytokines on Progesterone Production 
and Cell Death in Bovine Luteal Cells 
Overall, progesterone production was higher in cultures of luteal cells 
from late stage CL compared to early stage CL (Figs. 12 and 13, P<0.05). 
However, there was no effect of Ad.GFP or Ad.CKI 8 transduction on 
progesterone production by these cultures, regardless of stage (Fig. 12 
and 13, P>0.05). In cultures exposed to adenovirus (Ad.GFP or 
Ad.CKI 8) and then treated with a FasL-containing cytokine cocktail 
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(IFN+TNF+FasL), the cytokine cocktail (FasL) increased progesterone 
production (P<0.05), but only in cultures from late stage CL (Fig. 13). 
Plated cell counts before and after treatment with the cytokine cocktail 
revealed that neither CK18 over-expression nor cytokine treatment 
affected the percent of cell death (P>0.05, Fig. 14). A TUNEL assay was 
utilized to identify apoptotic cells after cytokine treatment (Fig. 15). 
Neither transduction nor cytokine treatment affected the percentage of 
TUNEL-positive, apoptotic cells (P>0.05, Fig. 15). Similarly, there was no 
effect of stage of CL on this outcome (P>0.05, Fig. 15). 
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Figure 4. Characterization of cytokeratin intermediate filaments in the 
bovine CL using flow cytometric analysis, immunoprecipitation, 
and western blot analysis. 
Figure 4a. 
50 '] 
* 45 | 
O 40 -
to
 o c ( 
£ 35 I 
J 30 •) 
eo 2 5 •] 
§ 20 i 







Early Stage CL Late Stage CL 
97kD— 
64 kD-




Percentage of bovine luteal cells from early and late stage CL stained 
positively for CK18 as detected by flow cytometry (Fig. 4a). More cells 
within the early stage CL expressed CK18 than within late stage CL (n=6-
9 CL/stage, P<0.05). Different letters denote significant differences 
(P<0.05). Western blot analysis of CK8 expression in total luteal lysate 
from early stage bovine CL, as well as following immunoprecipitation with 
anti-CK18 antibody. (Fig. 4b). Immunoprecipitation using anti-CK18 
antibody enhanced CK8 expression (lane 3) compared to that found in 
total luteal lysate (lane 1). 
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Figure 5. Fas expression on bovine luteal cells from early and late stage 
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Figure 5d. 
Early Stage CL Late Stage CL 
Freshly dissociated luteal cells from early and late stage CL were 
characterized for total Fas and surface Fas expression. A higher 
percentage of cells expressed Fas in early stage CL compared to late 
stage CL (Fig. 5a). In addition, more cells expressed Fas on their cell 
surface in the early stage CL than the late stage (Fig. 5b). Comparison of 
the relative percent of cells expressing total Fas (grey bars) in relation to 
those expressing Fas on their cell surface (black bars; Fig. 5c). Bars 
represent mean ± SEM (n=4-9 CL/stage). Different letters denote 
significant differences (P<0.05). Confocal image (Fig. 5d) of luteal cell 
fluorescently stained for Fas (green) is shown with propidium iodide-
counterstained nucleus (red). 
51 
Figure 6. Fluorescent detection of GFP and CK18 within cultured bovine 
luteal cells of early stage CL after adenovirus transduction. 
DAPI GFP CK18 Merged 
Representative fluorescent photomicrographs (40x objective) of bovine 
luteal cell cultures from early stage CL following adenovirus transduction 
with control media (CTL; Fig. 6a-d), mock vector (Ad.GFP; Fig. 6e-h), or 
CK18 vector (Ad.CK18; Fig. 6i-l). GFP present in the cells indicated in 
green (Fig. 6b, 6f, 6j). CK18 staining indicated in red (Fig. 6c, 6g, 6k). 
Merged images include DAPI (Fig. 6a, 6e, 6i), GFP, and CK18 staining 
(Fig. 6d, 6h, 61). 
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Figure 7. Example of filamentous and aggregate CK18 staining with 
bovine luteal cells. 
Representative fluorescent photomicrograph (40x objective) of bovine 
luteal cells from late stage CL following transduction with Ad.CK18. 
Arrows indicate individual cells demonstrating either filamentous CK18 
staining or aggregate CK18 staining (green). 
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Figure 8. Fluorescent detection of GFP and CK18 within cultured bovine 
luteal cells of late stage CL after adenovirus transduction. 
DAPI GFP CK18 Merged 
Representative fluorescent photomicrographs (40x objective) of bovine 
luteal cell cultures from late stage CL following adenovirus transduction 
with control media (CTL; Fig. 8a-d), mock vector (Ad.GFP; Fig. 8e-h), or 
CK18 vector (Ad.CK18; Fig. 8i-l). GFP present in the cells indicated in 
green (Fig. 8b, 8f, 8j). CK18 staining indicated in red (Fig. 8c, 8g, 8k). 
Merged images include DAPI (Fig. 8a, 8e, 8i), GFP, and CK18 staining 
(Fig. 8d, 8h, 81). 
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Figure 9. Effect of adenovirus transduction on microtubules within early 
stage bovine luteal cells. 
DAPI GFP Microtubules Merged 
Representative fluorescent photomicrographs (40x objective) of bovine 
luteal cell cultures from early stage CL following adenovirus transduction 
with control media (CTL; Fig. 9a-d), mock vector (Ad.GFP; Fig. 9e-h), or 
CK18 vector (Ad.CK18; Fig. 9i-l). GFP present in the cells indicated in 
green (Fig. 9b, 9f, 9j). Microtubule staining indicated in red (Fig. 9c, 9g, 
9k). Merged images include DAPI (Fig. 9a, 9e, 9i), GFP, and microtubule 
staining (Fig. 9d, 9h, 91). 
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Figure 10. Effect of adenovirus transduction on microtubules within late 
stage bovine luteal cells. 
DAPI GFP Microtubules Merged 
Representative fluorescent photomicrographs (40x objective) of bovine 
luteal cell cultures from late stage CL following adenovirus transduction 
with control media (CTL; Fig. 10a-d), mock vector (Ad.GFP; Fig. 10e-h), 
or CK18 vector (Ad.CK18; Fig. 10i-l). GFP present in the cells indicated 
in green (Fig. 10b, 10f, 10j). Microtubule staining indicated in red (Fig. 
10c, 10g, 10k). Merged images include DAPI (Fig. 10a, 10e, 10i), GFP, 
and microtubule staining (Fig. 10d, 10h, 101). 
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Figure 11. Effect of adenovirus transduction with either mock vector (Ad. 
GFP) or CK18-containing vector (Ad.CK18) on Fas surface 
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Ad.GFP Ad.CK18 CTL Ad.GFP Ad.CK18 
Flow cytometric histogram of Fas surface expression on bovine luteal 
cells from late stage CL from a single experiment (Fig. 11a). As a result 
of three separate experiments, neither treatment with mock vector 
(Ad.GFP) nor with CK18-containing vector (Ad.CK18) affected the 
number of cells expressing Fas on their cell surface (Fig. 11b, P>0.05). 
There was no significant effect on the relative mean fluorescent intensity 
of Fas expression on the surface of late stage luteal cells after 
adenovirus transduction with either vector (Fig. 11c, P>0.05). Bars 
represent the mean ± SEM (n=3 CL). Different letters indicate significant 
differences (P<0.05). 
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Figure 12. Progesterone production by early and late stage bovine luteal 
cells after adenovirus transduction. 
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CTL Ad.GFP Ad.CK18 
Progesterone production by bovine luteal cells cultured from early and 
late stage CL was assessed via RIA and adjusted relative to 100,000 
transduced cells. Bars represent mean ± SEM. Difference letters 
represent significant differences (P<0.05). 
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Figure 13. Progesterone production by early and late stage bovine luteal 
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Progesterone production by bovine luteal cells cultured from early and 
late stage CL was assessed via RIA adjusted relative to 100,000 
transduced cells. Progesterone production was highest in luteal cells 
cultured from late stage CL and exposed to cytokine cocktail 
(IFN+TNF+FasL). However, there was no different in progesterone 
production by cultured luteal cells transduced by mock vector compared 
to CK18-containing vector, regardless of stage. Bars represent mean ± 
SEM. Difference letters represent significant differences (P<0.05). 
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Figure 14. Effect of cytokine treatment on adenovirus-transduced luteal 
cells from early and late stage CL. 
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Cell death counts were determined before and after 24-hour FasL-
containing cytokine treatment. Bars represent percent of cell death 
relative to control ± SEM. Different letters indicate significant differences 
(P<0.05). 
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Figure 15. Effect of cytokine treatment subsequent to adenovirus 
transduction on percent of TUNEL-positive cells in cultures of 
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Apoptosis of transduced cultured bovine luteal cells from early and late 
stage CL after FasL-containing cytokine treatment for 24 hours. Bars 




The current study explored the potential role of CK8/18 
intermediate filaments in the trafficking of Fas within bovine luteal cells 
and the susceptibility of these cells to FasL-induced apoptosis. To 
understand the underlying mechanisms of FasL-induced apoptosis, luteal 
cells from early and late stage CL were characterized in terms of the 
abundance of CK18-containing intermediate filaments and the expression 
of the Fas death receptor. In a previous study [118], we observed a 
decrease in cells expressing CK18-containing filaments as the bovine CL 
ages. These previous observations have been confirmed in this study. 
CK18-containing filaments were expressed in more cells cultured from 
early stage CL (Day 5; 46% positive cells) than late stage CL (Day 16-18; 
26% positive). The temporal pattern of cellular expression of CK18-
containing filaments in the CL during the bovine estrous cycle is 
consistent with the previous reports [117, 118]. However, there are some 
differences among the studies, particularly with the characterization of the 
late stage CL. In particular, the current study found an average of 26% of 
luteal cells obtained from the CL of heifers and cows expressed CK18 
filaments. This differs from a previous study in our laboratory [118] in 
which -5% of cells dissociated from late stage CL expressed CK18. The 
disparity may be in part accounted for by differences in staging the CL, 
and quite possibly, developmental differences between heifers and cows. 
The current study utilized both heifers and cows, whereas the previous 
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studies used only lactating dairy cows. Heifers typically have a shorter 
estrous cycle than cows (averaging 20 days as opposed to 21 days for 
dairy cows) [9]. Additionally, variation in staging of CL based upon time 
of standing estrus or ovulation could vary greatly between heifers and 
cows, especially during the latter half of the luteal phase. These 
differences could extend to the relative expression of CK18-containing 
filaments in the CL at this time. 
CK intermediate filaments consist of obligate type l/type II pairs 
[112-115, 131]. CK18 forms filaments with CK8 most frequently [113-
115]. While CK8/18 filaments have been demonstrated in rat [120] and 
human [119] CL, until now only CK18 has been identified within the 
bovine CL [117, 118]. Immunoprecipitation was used in the current study 
to show CK intermediate filaments within the bovine CL consist of a 
heterodimer of CK8 and CK18 protein. Collectively, the results suggest 
CK8/18 intermediate filaments occur in the CL of several species and 
emphasize the potential role of CK filaments in the CL. 
Flow cytometric analysis of Fas expression in luteal cells from early 
and late stage CL yielded results that were unexpected. Based upon 
previous studies [20, 72, 86, 88, 95], we hypothesized that Fas protein 
expression would be higher in cells from late stage CL than from early 
stage CL. We also hypothesized that the percentage of cells expressing 
Fas on their surface would be higher for late stage CL than early stage 
CL. However, the results of the current study failed to support these 
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hypotheses. A higher percentage of cells from early stage CL expressed 
both total Fas and cell surface Fas than cells from the late stage CL. 
Several possibilities exist for these observations. Firstly, it is conceivable 
that soluble decoy receptors and/or splice variants of Fas exist on luteal 
cells, because decoy receptors and splice variants have been detected in 
other cell types from both mice and humans [91, 102, 132-134]. It is 
possible that some splice variants may be indistinguishable from native 
Fas by the methods of detection used in the current study. Secondly, Fas 
receptors at the surface of early stage luteal cells may be involved in pro-
survival mechanisms [101, 102]. Both the expression of Fas and all the 
potential roles of Fas within the bovine CL require further investigation. 
The concept that CK8/18 intermediate filaments influence Fas 
receptor expression and apoptosis in bovine CL is based upon previous 
work conducted with hepatocytes [111]. Gilbert and colleagues [111] 
showed that CK8/18 filaments prevent trafficking of Fas from the Golgi 
complex to the cell surface. The authors used knockdown studies in 
mice to show that the presence of these intermediate filaments prevented 
translocation of the Fas receptor to the cell surface, thereby decreasing 
susceptibility to Fas-mediated apoptosis. Here, we over-expressed CK18 
protein within cultured bovine luteal cells of early and late stage CL to 
determine if CK18 filaments have a similar role in the regulation of Fas 
movement to the cell surface. We chose to over-express CK18 rather 
than its partner, CK8, because evidence suggests that CK18 is degraded 
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more quickly than CK8 during filament polymerization [114]. Thus, if 
CK18 is the limiting factor for filament formation in luteal cells of late 
stage CL, expression of CK18 via adenovirus transduction should re-
establish CK8/18 filament formation within the cell. However, over-
expression of CK18 instead resulted in CK18-containing aggregates 
rather than filaments. These aggregates were not observed in cultures 
treated with control media or mock vector, indicating that neither the viral 
vector nor GFP expression induced CK18 aggregation. It appears that 
CK18 may not be the limiting protein for filament formation. Several 
potential explanations for the failure of CK18 to form complete 
intermediate filaments exist, including the known short half-life for CK 
proteins [135] and the need for filament components in equimolar 
amounts [115, 136]. 
The fact that the CK18 gene introduced via adenovirus vector is 
human CK18 may present a problem. However, this is unlikely. Others 
have shown CK intermediate filaments form even when each cytokeratin 
composing the pair is not from the same species [136]. However, several 
in vitro studies indicate a necessity for each CK monomer to be present 
in equimolar concentrations [115, 136] An over-abundance of one type of 
CK protein may result in the aggregation or degradation of the protein 
rather than dimerization with another type of CK. In the current 
investigation, we utilized an adenovirus vector containing a 
cytomegalovirus promoter. The CMV promoter is a strong, constitutive 
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transcription factor capable of inducing high target protein expression 
[137]. Hence, CK18 expression in the current study was essentially 
excessive and unregulated. Research by Nakamichi et al. [138] 
suggested over-expression of CK18 may actually be toxic to cells due to 
its tendency to cause CK aggregation. The aggregates also affected 
microtubule organization after 2 days of culture [138]. They also 
determined that complementary amounts of CK8 suppress this tendency 
[138]. We did not observe any adverse effect of CK18 aggregation on 
microtubules in the current study. Interestingly, in cells of early stage CL, 
both aggregates and filaments were detectable in the same cell. Another 
important feature of intermediate filaments is that individual proteins have 
a relatively short half-life in vivo, about an hour or less [135]. Future 
explorations of over-expression of CK18 should consider two important 
factors: the expression of CK8 in equimolar amounts and the potential of 
using an inducible promoter. 
In spite of the unsuccessful effort to induce CK filament formation in 
bovine luteal cells, the protein of interest, CK18, was successfully over-
expressed in cultures from both early and late stage CL. This prompted 
us to instead determine the effect of CK18 over-expression and 
aggregation on the function and viability of luteal cells. Neither the 
adenovirus nor the aggregation of CK18 impaired microtubule formation 
within the cells, regardless of CL stage. Similarly, neither the vector nor 
the aggregates altered progesterone production by the cells. These 
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experiments, to our knowledge, are among the first to demonstrate 
successful adenoviral transduction and expression in primary cultures of 
bovine luteal cells. Therefore, an important finding is that adenovirus 
infection alone is not detrimental to cytoskeletal architecture (i.e. 
microtubules and intermediate filaments), progesterone production, or 
viability. Moreover, we determined CK18 over-expression results in CK 
aggregation, but this too is not detrimental to the cells. 
A primary focus of this study was to investigate the effects of CK18 
over-expression on Fas surface expression in late stage luteal cells. We 
observed no noticeable impact on Fas surface expression in these cells 
following over-expression of CK18. Neither the percentage of cells 
expressing Fas nor the intensity of Fas on the cell surface was affected 
by CK18 aggregation. However, while the experiments overall showed 
no significant impact of transduction on Fas surface expression, in all 
three experiments Ad.CKI 8 treatment resulted in a decrease in Fas 
surface expression, ranging from minimal (5.6% decrease in percent of 
cells/5.7% decrease in MFI) to substantial (41% decrease in percent of 
cells/12.7% decrease in MFI). These results warrant further exploration. 
Toivola et al. [116] suggested that CK intermediate filaments may be 
involved in protein targeting or localization. Additionally, Inada et al. [139] 
provided evidence that CK8/18 filaments sequester an adaptor protein, 
TRADD, involved in TNF-induced apoptosis. Subsequent to their 
observations regarding CK8/18 and Fas interactions in hepatocytes, 
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Gilbert et al. [140] recently demonstrated a role for CK8/18 filaments in 
cytochrome c release after Fas activation. Therefore, it remains plausible 
that CK18 is an intermediate component in the regulation of Fas 
expression at the cell surface and/or Fas-mediated apoptosis. 
A further objective of this study was to investigate the effects of 
CK18 over-expression on FasL-induced apoptosis of cultured luteal cells. 
The combination of IFNy with TNFa induces apoptosis of bovine luteal 
cells after 48 hours [74], resulting in up to 50% death [72]. Adding FasL 
to the cytokine cocktail results in -85% death [72]. The rationale for this 
seemingly synergistic action of cytokines is that IFNy and TNFa enhance 
the effect of FasL by enhancing the expression and/or signaling of the 
Fas receptor. In order for FasL to induce Fas-mediated apoptosis, 
sufficient numbers of Fas receptor must be available at the cell surface to 
aggregate, form the DISC, and then initiate intracellular apoptotic 
signaling [83, 91, 101]. IFNy and TNFa increase Fas mRNA [72, 100] 
and protein [100] in cultured bovine luteal cells, but it is not known 
whether these cytokines enhance Fas expression on the luteal cell 
surface. Based on results for from the current study, the potential exists 
for early stage cells to be more susceptible to FasL-induced apoptosis 
than late stage cells. However, the regulation of the Fas receptor in early 
stage luteal cells has not yet been fully explored, and neither early nor 
late stage luteal cells were more susceptible to cell death. 
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In both control and cytokine-treated cells, progesterone production 
was highest from late stage luteal cells. Additionally, progesterone 
production was increased only in cultures from late stage CL when 
exposed to the FasL-containing cytokine cocktail. If late stage luteal cells 
are more susceptible to cytokine-induced cell death, then the 
progesterone produced may provide a protective mechanism in culture. 
A protective role for progesterone in cultures of bovine luteal cells has 
been demonstrated previously [100, 141]. Okuda et al. [141] showed that 
the addition of a progesterone antagonist decreases cell viability. The 
decrease in viability is further enhanced by the addition of FasL, and the 
progesterone anatagonist also increases Fas and caspase-3 mRNA 
[141]. Additionally, Bowolaksono et al. [100] demonstrated that in 
cultures where progesterone was increased due to treatment, the effects 
of TNF+IFN+FasL on cell death and Fas mRNA were negated. Perhaps, 
FasL may have been effective in our experiments had we controlled for 
progesterone production within the cultured media. Further explorations 
in this area should consider the effects of progesterone on the cultured 
luteal cells. 
Overall, this study confirmed CK filament expression is 
highest in luteal cells of early stage CL and diminishes as luteal 
regression becomes imminent. Moreover, we demonstrated that the CK 
filaments consist primarily of CK8 dimerized with CK18. To our 
knowledge, this study is the first to characterize expression of Fas on the 
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surface of luteal cells and that the temporal pattern of Fas expression 
mimics CK18 filament expression. Although this finding is counter-
intuitive to previous reports in the literature, it directs attention to the need 
for further investigation of the regulatory factors of the Fas pathway in this 
tissue. Importantly, we discovered adenovirus transduction can be 
achieved in primary cultures of bovine luteal cells with good uptake 
efficiency and protein expression. No evidence of adenovirus toxicity 
was observed. While over-expression of CK18 protein was achieved, we 
discovered that aggregation rather than filament formation occurred. 
Therefore, it may be necessary to adjust the expression of both CK8 and 
CK18 proteins to assess the role of CK8/18 filaments in these cells. 
CK18 knockdown is also plausible based upon our ability to transduce 
this cell type, and the knowledge that these interventions lead to filament 
disruption [114]. Overall, the potential still exists that CK8/18 filaments 
influence FasL-induced death of luteal cells. The methods developed 
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1. Plate cells the night before in complete media (i.e. with serum) for 80-90% 
confluency at the time of transduction. 
2. Dilute crude viral stocks (CVL) to desired titer in serum-free media with 
pen-strep. 
3. Remove media and replace with virus-containing media (1ml per 1X106 
cells). Incubate for 1 or 1 and Vz hrs at 37°C, 5%C02, shaking gently 
every 15 min (if possible). 
4. Remove virus-containing media, and replace with fresh media with 5% 
serum and incubate for 16-24 hrs. 
5. Remove media and replaced with pre-equilibrated media and cells were 
ready for further treatments. 
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